- All sections
- C - Chemistrymetallurgy
- C07K - Peptides
- C07K 14/715 - ReceptorsCell surface antigensCell surface determinants for cytokinesReceptorsCell surface antigensCell surface determinants for lymphokinesReceptorsCell surface antigensCell surface determinants for interferons
Patent holdings for IPC class C07K 14/715
Total number of patents in this class: 2760
10-year publication summary
|
102
|
98
|
172
|
153
|
190
|
226
|
225
|
269
|
264
|
215
|
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
Principal owners for this class
| Owner |
All patents
|
This class
|
|---|---|---|
| Regeneron Pharmaceuticals, Inc. | 4426 |
99 |
| Altor BioScience, LLC | 76 |
54 |
| Xencor, Inc. | 392 |
40 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 2903 |
39 |
| The Trustees of the University of Pennsylvania | 4376 |
31 |
| Immunitybio, Inc. | 464 |
29 |
| The Board of Trustees of the Leland Stanford Junior University | 6526 |
28 |
| National University of Singapore | 2511 |
27 |
| Cytune Pharma | 39 |
25 |
| Vib VZW | 883 |
25 |
| Amgen Inc. | 4163 |
24 |
| Singapore Health Services Pte Ltd | 472 |
23 |
| The Regents of the University of California | 20268 |
22 |
| Universiteit Gent | 1351 |
22 |
| Novartis AG | 10626 |
21 |
| Dana-Farber Cancer Institute, Inc. | 2621 |
21 |
| FATE Therapeutics, Inc. | 212 |
21 |
| Synthekine, Inc. | 111 |
21 |
| Autolus Limited | 260 |
20 |
| Bristol-myers Squibb Company | 4824 |
19 |
| Other owners | 2149 |